Compare FOR & MGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FOR | MGTX |
|---|---|---|
| Founded | 2005 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.2B |
| IPO Year | 2007 | 2018 |
| Metric | FOR | MGTX |
|---|---|---|
| Price | $26.68 | $12.85 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | ★ $32.67 | $24.57 |
| AVG Volume (30 Days) | 93.3K | ★ 699.6K |
| Earning Date | 04-21-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 33.02 |
| EPS | ★ 1.63 | 1.30 |
| Revenue | ★ $1,662,400,000.00 | $81,391,000.00 |
| Revenue This Year | $0.34 | $141.38 |
| Revenue Next Year | $7.73 | N/A |
| P/E Ratio | $16.51 | ★ $10.20 |
| Revenue Growth | 10.14 | ★ 144.57 |
| 52 Week Low | $22.81 | $6.62 |
| 52 Week High | $32.06 | $15.35 |
| Indicator | FOR | MGTX |
|---|---|---|
| Relative Strength Index (RSI) | 31.98 | 41.39 |
| Support Level | $26.01 | $12.39 |
| Resistance Level | $27.71 | $15.33 |
| Average True Range (ATR) | 0.65 | 0.65 |
| MACD | -0.21 | -0.21 |
| Stochastic Oscillator | 4.40 | 7.69 |
Forestar Group Inc is a residential lot development company engaged in land acquisition and development for the sale of finished single-family residential lots to local, regional, and national homebuilders. The company operates through a single real estate segment, which acquires land, installs infrastructure for residential communities, and generates all revenue from lot sales. Its communities mainly support entry-level, first-time move-up, and active-adult homes, with certain communities also marketed to build-to-rent operators. The company generally invests in entitled, short-duration projects that can be developed in phases to align lot production with market demand and support efficient capital deployment.
MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company focused on developing targeted therapies for diseases with high unmet need, including radiation-induced xerostomia, Parkinson's disease, and AIPL1-associated retinal dystrophy. The company's pipeline is supported by end-to-end in-house manufacturing capabilities, including GMP viral vector production, plasmid manufacturing, and quality control, enabling development from IND to commercial supply. It also utilizes proprietary platforms in viral vector optimization and riboswitch-based gene regulation to enhance efficacy and reduce dosage. The company operates in the United States, the United Kingdom, and the European Union.